TheraMicro appears in FDA premarket records as the applicant for the TeKBrace Knotless Anchor, cleared through a special 510(k) pathway. The filing record identifies the applicant at a Cordova, Tennessee address and lists Christine Scifert as contact. The supplied collection contains one linked 510(k) record, decided as substantially equivalent, and no recall records. That count reflects the supplied filings as of the snapshot date, not total company sales, total portfolio or safety performance. [1][2][7]
Documented 510(k) clearances
K263352 covers the TeKBrace Knotless Anchor, received September 23, 2026 and decided October 21, 2026 as substantially equivalent. The record lists product code MBI, regulation number 888.3040, orthopedic advisory committee and a special clearance type. The FDA letter for the same submission states the device is intended to add the use of smaller width TeKBrace implants with the TeKBrace Knotless Anchors, and that those implants are identical to TeKBrace Solo Tissue Reinforcement Devices cleared under K251063 and K261621. [1][2][7]
An earlier TeKBrace Knotless Anchor submission, K253538, was dated March 6, 2026, with the device received February 5, 2026. Its determination letter describes performance testing of insertion and removal torque, torque capacity and pullout before and after fatigue for the subject anchors and predicate Arthrex and Artelon anchors, conducted in accordance with ASTM F543-07. The letter concludes the subject device is substantially equivalent to the predicate devices. [3]
TeKBrace platform and kit contents
TheraMicro's own site describes TeKBrace as soft tissue reinforcement and states that each sterile-packed TeKBrace Kit includes the scaffold, anchors and single-use instruments for implantation. The same page states the product is protected by U.S. Patent No. 12,544,208 and attributes claims about tensile strength, open-weave structure and tissue-mimicking biomechanics to data and references on file. Those performance statements originate with the publisher and are not independently verified here. [4]
A separate TeKBrace overview page frames the product as tendon and ligament reinforcement and notes that federal law in the USA restricts sale and use to, or on the order of, a physician. The site navigation also lists TeKForce all-suture anchors and a knotless syndesmosis system, alongside ZOrigin and other products such as AlloStat GFx and CentaVisc. [9][6]
Applicant identity and corporate materials
The FDA record names TheraMicro as applicant and correspondent at 51 Germantown Ct., Cordova, TN 38018, with Christine Scifert as contact. The K253538 letter addresses Christine Scifert as Head of QA/RA at Theramicro, 51 Germantown Court Suite 200, Cordova, Tennessee. These are filing addresses, not a verified headquarters. No parent, subsidiary or brand ownership relationship is established in the public documents. [1][2][3]
TheraMicro's homepage describes a mission to treat musculoskeletal disease with minimally invasive solutions and presents TeKForce, TeKBrace and ZOrigin as product lines, with contact routes for reimbursement questions and distributor interest. The site content is the company's own published material. [6]
Scope limits of the supplied record
The supplied collection links one 510(k) record, K263352, with a single substantially equivalent decision, and no recall entries. A broader openFDA query for decisions between October 17 and November 16, 2026 returned 159 total results, which is a database query count rather than a measure of TheraMicro activity. The collection counts describe the supplied filings only and should not be read as total company sales, total portfolio or safety performance. [1][5]



